- Voyager Therapeutics Inc (NASDAQ:VYGR) unveiled its prioritized therapeutic pipeline focusing on tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's and SOD1 ALS.
- For GBA1 Parkinson's, a non-human primate (NHP) capsid evaluation study is currently underway.
- Voyager intends to select a development candidate in 1H of 2023, initiate a dose range finding study in NHPs in 2H of 2023, and initiate GLP toxicology studies in 2024.
- Voyager anticipates an IND filing in 2025.
- For SOD1 gene silencing, an NHP capsid evaluation study is currently underway. The company intends to select a development candidate in 2022, complete an NHP dose range finding study in 2023, initiate GLP toxicology studies in 1H of 2024, and file an IND in 2024.
- On the partnership front, the company believes that Pfizer Inc (NYSE: PFE) and Novartis AG (NYSE: NVS) TRACER capsid collaborations are going well with option exercise decisions upcoming in Q4 2022 and Q1 2023, respectively.
- Voyager expects that its cash, cash equivalents, and marketable securities will be sufficient to meet Voyager's planned operating expenses and capital expenditure requirements into 2024.
- Price Action: VYGR shares are down 6.02% at $7.02 during the market session on the last check Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
